For people using these drugs, the study raises practical questions about planning care over years. Decisions about when to start, how long to continue, and what supports to add if treatment ends matter for daily life and long-range risk. Health systems and clinicians will need clear strategies to help patients maintain gains and manage shifting risks if therapy is interrupted or stopped.
This topic connects to human potential because stable health underpins learning, work, caregiving, and community participation. Exploring how to preserve cardiovascular benefits—through follow-up care, lifestyle supports, or alternative therapies—ties directly to fairness and inclusion in health outcomes. Read the full article to learn what the research found and how its findings might shape long-term care choices for people using GLP-1 treatments.
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
